Regenera to list in early June
Wednesday, 19 May, 2004
The CEO of Perth-based biotech Regenera, Tony Fitzgerald, said today that he expected the company’s offer to close next week, oversubscribed, ready for a June listing.
Regenra plans to raise AUD$8 million to develop its therapy for age related macular degeneration AMD – a condition in which damage to the retina causes visual impairment. The therapy involves injecting a steroid, triamciolone acetomide, into the back of the eye every six months.
“We have had a very good response in a difficult market,” said Fitzgerald. He said there had been significant Australian investment and that a number of international opthamologists were also supporting the company.
Fitzgerald plans to gain both TGA approval and an international licence for Regenera's product, possibly as a co-therapy with another AMD treatment.
Mouth bacteria linked to increased head and neck cancer risk
More than a dozen bacterial species that live in people's mouths have been linked to a...
Life expectancy gains are slowing, study finds
Life expectancy at birth in the world's longest-living populations has increased by an...
Towards safer epilepsy treatment for pregnant women
New research conducted in organoids is expected to provide pregnant women with epilepsy safer...
